Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Foghorn Therapeutics Inc | FHTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.98 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.98 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.70 - 9.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 5.98 | USD |
Foghorn Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 248.58M | 42.57M | - | 34.16M | -98.43M | -2.31 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Foghorn Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FHTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.00 | 6.5199 | 5.51 | 5.92 | 52,269 | -0.02 | -0.33% |
| 1 Month | 7.16 | 8.05 | 4.80 | 5.96 | 72,222 | -1.18 | -16.48% |
| 3 Months | 6.79 | 8.44 | 4.80 | 6.52 | 92,175 | -0.81 | -11.93% |
| 6 Months | 3.50 | 8.44 | 2.70 | 5.38 | 123,592 | 2.48 | 70.86% |
| 1 Year | 5.27 | 9.97 | 2.70 | 5.79 | 105,947 | 0.71 | 13.47% |
| 3 Years | 9.86 | 24.34 | 2.70 | 11.97 | 143,566 | -3.88 | -39.35% |
| 5 Years | 18.12 | 28.265 | 2.70 | 12.73 | 140,590 | -12.14 | -67.00% |
Foghorn Therapeutics Description
| Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. |
